Advertisement

 

 

Anti-PD-1 Therapy OK for Most with HIV.

Anti-PD-1 Therapy OK for Most with HIV.
Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Cancer discovery 2017 12 13() doi 10.1158/2159-8290.CD-NB2017-174

Abstract

The PD-1 inhibitor pembrolizumab poses no significant risks for patients with HIV and cancer, according to data presented at a recent meeting of the Society for Immunotherapy of Cancer. The findings suggest that patients with HIV should no longer be excluded from clinical trials testing checkpoint inhibitors and other novel therapies for cancer.

Submit a Comment

Your email address will not be published. Required fields are marked *

nine − four =

[ HIDE/SHOW ]